209 results on '"Davies, F E"'
Search Results
2. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
3. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
4. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
5. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
6. Clinical value of molecular subtyping multiple myeloma using gene expression profiling
7. P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY)
8. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation
9. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
10. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
11. Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?
12. Patients in the MRC Myeloma XI trial receiving induction chemotherapy for newly diagnosed multiple myeloma containing dexamethasone at full or moderated dose have significantly reduced half-life of IgG: 259
13. The NCRI Myeloma XI trial for newly diagnosed symptomatic multiple myeloma (NDMM); second primary malignancy (SPM) incidence when lenalidomide is used as an induction and maintenance treatment option: 205
14. Quadruplet verus sequential triplet induction therapy approaches to maximise response for transplant eligible (TE), newly diagnosed myeloma patients (NDMM) in the NCRI Myeloma XI trial: 1
15. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR
16. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
17. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
18. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma
19. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
20. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality
21. Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application
22. Minimal residual disease is highly predictive of outcome in myeloma: results from MRC Myeloma IX: 28
23. Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma: 47
24. Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin
25. A Molecular Characterization of 17p Deletion in Myeloma, Related to Maintenance Thalidomide Outcome: B455
26. Association of Genetic Variants with FISH-Based Karyotyping Status in Multiple Myeloma Patients: B405
27. DSG2, a Novel Key Player Regulating Cell Proliferation and Cell Cycle Progression in t(4;14) Myeloma: B403
28. MRC Myeloma IX: Preliminary Results from The Intensive Pathway Study: A546
29. MRC Myeloma IX: Preliminary Results from the Non-Intensive Study: A547
30. MRD Studies in MM: Data from the MRC Myeloma IX Trial: A479
31. Prospective Study of Serum FLC and Other M-Protein Assays: When and How to Measure Response?: A346
32. Position statement on the use of bortezomib in multiple myeloma
33. Deletion of 16q identified by FISH is an independent adverse prognostic marker in multiple myeloma: 2
34. Proteomics and the haematologist
35. The use of genetic microarray analysis to classify and predict prognosis in haematological malignancies
36. Frizzled-related protein (FRZB) and signalling via the Wnt pathway are implicated in the pathogenesis of multiple myeloma (MM)
37. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression
38. Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma
39. TRUE SPECTRUM OF 14q32 TRANSLOCATIONS IN MULTIPLE MYELOMA
40. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
41. ANEUPLOIDY IN MULTIPLE MYELOMA IS A LATE EVENT, NOT AFFECTING THE CD20 (+) B CELL POPULATION
42. Trisomy 12 is seen within a specific subtype of B-cell chronic lymphoproliferative disease affecting the peripheral blood/bone marrow and co-segregates with elevated expression of CD11a
43. The Use of Biological Variables to Predict Outcome in Multiple Myeloma
44. Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia
45. Mutations in CRBNand other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
46. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
47. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
48. Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach
49. Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
50. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.